A Comprehensive Review: Inflammatory Bowel Disease And Its Global Perspective
Article Sidebar
Main Article Content
Abstract
Inflammatory bowel disease (IBD), comprising ulcerative colitis (UC) and Crohn’s disease (CD), represents a persistent gastrointestinal inflammatory condition. Initially labeled as a "Western disease," IBD was predominantly associated with Western lifestyles, but a shift in dietary and lifestyle patterns has led to a noticeable rise in Asian populations. The global prevalence of IBD reached 6.8 million cases in 2017, with a subsequent decrease to 4.9 million cases in 2019, showcasing a dynamic occurrence. The multifactorial pathogenesis involves genetic susceptibility, environmental factors, and an aberrant immune response to the gut microbiota. IBD is classified into CD, affecting any part of the gastrointestinal tract, and UC, limited to the colon and rectum. A third category, IBD-unspecified (IBD-U), is utilized when the inflammation's origin is unclear. Complications, including strictures, fistulas, and colorectal cancer, emphasize the disease's severity. Treatment options range from aminosalicylates to biologics, with emerging therapies and a focus on the mucosal antibacterial barrier offering potential advancements. Global healthcare organizations, recognizing IBD as a global ailment, aim to summarize epidemiological patterns to guide interventions. In study on global burden of disease 40 million cases were reported, prevalence of more than 1 percent of total global incidence has been seen worldwide, 41.00 thousand deaths, and 1622.50 thousand DALYs globally in 2019. While advancements have been made, further research is crucial to improve prevention and treatment strategies. The shift in the pathogenic focus towards mucosal antibacterial barriers presents a potential avenue for future developments, offering hope for enhanced outcomes and improved quality of life for individuals affected by IBD
Downloads
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
Gu Z, Gu J, Liu P. The effectiveness of continuity of care in patients with inflammatory bowel disease: a systematic review. BMC Gastroenterol. 2024;24:24. doi:10.1186/s12876-023-03109-3. DOI: https://doi.org/10.1186/s12876-023-03109-3
Ledergerber M, Lang BM, Heinrich H, et al. Abdominal pain in patients with inflammatory bowel disease: association with single-nucleotide polymorphisms prevalent in irritable bowel syndrome and clinical management. BMC Gastroenterol. 2021; 21:53. doi:10.1186/s12876-021-01622-x. DOI: https://doi.org/10.1186/s12876-021-01622-x
Zhou JL, Bao JC, Liao XY, et al. Trends and projections of inflammatory bowel disease at the global, regional and national levels, 1990–2050: a Bayesian age-period-cohort modeling study. BMC Public Health. 2023; 23:2507. doi:10.1186/s12889-023-17431-8. DOI: https://doi.org/10.1186/s12889-023-17431-8
GBD 2017 Inflammatory Bowel Disease Collaborators. The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol. 2019;21 October. doi:10.1016/S2468-1253(19)30333-4. DOI: https://doi.org/10.1016/S2468-1253(19)30333-4
Dharni K, Singh A, Sharma S, et al. Trends of inflammatory bowel disease from the Global Burden of Disease Study (1990-2019). Indian J Gastroenterol. 2023. doi:10.1007/s12664-023-01430-z. DOI: https://doi.org/10.1007/s12664-023-01430-z
Wang R, Li Z, Liu S, et al. Global, regional and national burden of inflammatory bowel disease in 204 countries and territories from 1990 to 2019: a systematic analysis based on the Global Burden of Disease Study 2019. BMJ Open. 2023;13:e065186. doi:10.1136/bmjopen-2022-065186. DOI: https://doi.org/10.1136/bmjopen-2022-065186
Ouahed J, Spencer E, Kotlarz D, et al. Very Early Onset Inflammatory Bowel Disease: A Clinical Approach With a Focus on the Role of Genetics and Underlying Immune Deficiencies. Inflamm Bowel Dis. 2020;26(6):820–42. DOI: https://doi.org/10.1093/ibd/izz259
Lautenschlager SA, Barry MP, Rogler G, et al. Lifestyle factors associated with inflammatory bowel disease: data from the Swiss IBD cohort study. BMC Gastroenterol. 2023;23:71. doi:10.1186/s12876-023-02692-9. DOI: https://doi.org/10.1186/s12876-023-02692-9
Health Union. Types of IBD [Internet]. Philadelphia: Health Union; 2018 [updated 2018 Dec 18; cited 2024 Jan 10]. Available from: https://inflammatoryboweldisease.net/types-of-ibd.
Imhann F, Van der Velde KJ, Barbieri R, et al. The 1000IBD project: multi-omics data of 1000 inflammatory bowel disease patients; data release 1. BMC Gastroenterol. 2019;19:5. doi:10.1186/s12876-018-0917-5. DOI: https://doi.org/10.1186/s12876-018-0917-5
Chen G, Lissoos T, Dieyi C, Null KD. Development and Validation of an Inflammatory Bowel Disease Severity Index Using US Administrative Claims Data: A Retrospective Cohort Study. Inflamm Bowel Dis. 2021;27(8):1177–1183. DOI: https://doi.org/10.1093/ibd/izaa263
Peyrin-Biroulet L, Panés J, Sandborn WJ, et al. Defining Disease Severity in Inflammatory Bowel Diseases: Current and Future Directions. Clin Gastroenterol Hepatol. 2016;14(3):348-354.e17. DOI: https://doi.org/10.1016/j.cgh.2015.06.001
Jang J, Jeong S. Inflammatory Bowel Disease: Pathophysiology, Treatment, and Disease Modeling. BioChip J. 2023;17:403–430. DOI: https://doi.org/10.1007/s13206-023-00118-y
Tavakoli P, Vollmer-Conna U, Hadzi-Pavlovic D, Grimm MC. A Review of Inflammatory Bowel Disease: A Model of Microbial, Immune and Neuropsychological Integration. Front Public Health Serv Syst Res. 2021. DOI: https://doi.org/10.3389/phrs.2021.1603990
Jin J. Inflammatory Bowel Disease. JAMA. 2014;311(19):2034. doi:10.1001/jama.2014.1664. DOI: https://doi.org/10.1001/jama.2014.1664
Sun Y, Li L, Xie R, Wang B, Jiang K, Cao H. Stress Triggers Flare of Inflammatory Bowel Disease in Children and Adults. Front Pediatr. 2019; 7:432. doi:10.3389/fped.2019.00432. DOI: https://doi.org/10.3389/fped.2019.00432
Stephen B Hanauer. Inflammatory Bowel Disease: Epidemiology, Pathogenesis, and Therapeutic Opportunities. Inflamm Bowel Dis. 2006;12(Suppl 1):S3–S9. doi:10.1097/01.MIB.0000195385.19268.68. DOI: https://doi.org/10.1097/01.MIB.0000195385.19268.68
Nakase H, Uchino M, Shinzaki S, et al. Evidence-based clinical practice guidelines for inflammatory bowel disease 2020. J Gastroenterol. 2021;56:489–526. DOI: https://doi.org/10.1007/s00535-021-01784-1
Cai Z, Wang S, Li J. Treatment of Inflammatory Bowel Disease: A Comprehensive Review. Front Med. 2021;8:765474. DOI: https://doi.org/10.3389/fmed.2021.765474
Vavricka SR, Schoepfer A, Scharl M, et al. Extraintestinal Manifestations of Inflammatory Bowel Disease. Inflamm Bowel Dis. 2015;21(8):1982-1992. DOI: https://doi.org/10.1097/MIB.0000000000000392
Holubar SD, Holder-Murray J, Flasar M, Lazarev M. Perioperative complications in inflammatory bowel disease. Inflamm Bowel Dis. 2011;17(7):1610-1619. DOI: https://doi.org/10.1002/ibd.21504
Higashiyama M, Hokari R. New and Emerging Treatments for Inflammatory Bowel Disease. Digestion. 2023;104(1):74–81. DOI: https://doi.org/10.1159/000527422
Cao L, Dayimu A, Guan X, et al. Global evolving patterns and cross-country inequalities of inflammatory bowel disease burden from 1990 to 2019: a worldwide report. Inflamm Res. 2024. DOI: https://doi.org/10.1007/s00011-023-01836-7
Stange EF. Current and future aspects of IBD research and treatment: The 2022 perspective. Front Gastroenterol. 2022;1 DOI: https://doi.org/10.3389/fgstr.2022.914371